Trials / Completed
CompletedNCT05372107
A Study of AG-80308 in Dry Eye Patients
A Multicenter, Double-Masked, Phase 1b Study Evaluating the Safety, Tolerability, and Dose-Response of Topical AG-80308 in Patients With Dry Eye Disease
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 84 (actual)
- Sponsor
- Allgenesis Biotherapeutics Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a multicenter, double-masked, randomized, parallel-group study with topical AG-80308 eye drops in dry eye patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AG-80308 | AG-80308 Eye Drop Solution |
Timeline
- Start date
- 2022-06-13
- Primary completion
- 2022-11-02
- Completion
- 2022-11-02
- First posted
- 2022-05-12
- Last updated
- 2022-11-29
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05372107. Inclusion in this directory is not an endorsement.